Eli Lilly is seeking approximately $8 billion through an investment-grade bond sale. The company will use the capital to fund its ongoing acquisition strategy. Recent multi-billion dollar deals include the purchases of Centessa Pharmaceuticals and Kelonia Therapeutics.
Lilly also committed an additional $4.5 billion to its manufacturing campus in Lebanon, Indiana. This brings the company's total investment in the state to over $21 billion since 2020.
The capital injection aims to scale production for blockbuster GLP-1 drugs Zepbound and Mounjaro. The facility will also produce the new oral drug Foundayo and future genetic medicines to meet surging global demand.